Mental Health

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, outlines the progression of treatment approaches for comorbid schizophrenia and substance use disorder.

The number of psychiatrists submitting more than 10 claims to Medicare Part B decreased by 16.8% from 2014 to 2022.

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and substance use disorders in an interview.

Prolonged immigration detention is significantly associated with worsened self-rated health, along with high rates of posttraumatic stress disorder (PTSD) and mental illness.

Researchers suspect unmet treatment needs contribute to the shorter life expectancy for patients living with attention-deficit/hyperactivity disorder (ADHD).

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

Among publicly insured children with mental health–related encounters, racial and ethnic disparities in telemental health use widened following the onset of the COVID-19 pandemic.

The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.

ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.

Doctors conducted suicide risk assessments for 42% of patients flagged by interruptive alerts, compared with only 4% with passive alerts.

Quantitative Medicaid managed care network adequacy standards were not associated with improved mental health (MH) care access among adults and those with MH conditions.

Sarah Ahmad, MBA, CEO of the Coalition for Affordable Quality Healthcare (CAQH), dives into the financial, physical, and emotional toll of neglecting women's health in an interview.

The most-read articles addressing mental health in 2024 spanned therapeutic advancements, research discoveries, and insight into enhanced practice guidelines.

Despite promising outcomes for certain conditions, use of psychedelics and MDMA-assisted therapies are associated with risks, especially as treatment use expands beyond controlled clinical settings.

Discover strategies for identifying, treating, and supporting those affected by seasonal affective disorder (SAD).

The Center on Health Equity & Access highlights news and expert insights on research, social determinants of health, and health policy.

While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.

Adults currently aging into Medicare utilized counseling and psychotherapy services at higher rates than those in prior cohorts at the same age.

There are significant financial and psychological burdens of abortion care in the US, especially for those traveling out of state due to local restrictions in the increasingly restrictive post-Dobbs landscape.

Researchers evaluated the lesser-known impact of telehealth treatments, including brief cognitive behavioral therapy (BCBT), to address the needs of individuals at risk of or recovering from suicidal ideation.

A recent retrospective, cross-sectional study found that detecting self-injurious thoughts and behaviors in youth requires improvement to ensure equitable identification of at-risk patients.

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients.

While some adversities, like peer aggression, lead to worsening mental health, others, such as community threat, may result in adaptive suppression of symptoms.

In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.

Financial toxicity and patient and staff wellness were well explored at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference, serving as the focal point of multiple posters and presentations.

The Center on Health Equity & Access is dedicated to reducing health care disparities by exploring innovative solutions, policies, and research that advance health equity for diverse populations.

The extent to which certified community behavioral health clinic expansion reaches different parts of the country remained unclear until this study, which measured the proportion of US counties and populations within the service areas.

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults.

This interview accompanies the third podcast in our National Recovery Month series with Kim MacDonald-Wilson, ScD, CPRP, senior program director, Recovery and Wellness Transformation, and Tracy Carney, CPS, CPRP, senior recovery and resiliency specialist, Community Care Behavioral Health Organization.

Results show that cognitive decline, combined with factors like smoking, obesity, and chronic health conditions, sharply increased the likelihood of premature death among patients with schizophrenia.